Stay updated with breaking news from Third Party Product. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
For the BFSI industry, the willingness of consumers to share data comes as a boon as it helps them provide tailor-made services for their customers. In other words, the fundamental question of how the right offer, right customer, the right moment, and the right channel can now be accomplished, , Demystifying Data, india, potential, BFSI industry
In a recently concluded roundtable organised by BW Businessworld with some of India’s top leaders associated with the finance sector, a wide range of topics were discussed, including the impact of the pandemic on the financial services industry , , financial services
Published: May 20, 2021 in the first quarter of 2021 for: VLA15, currently the only clinical stage vaccine candidate against Lyme disease Initiation of additional Phase 2 trial to accelerate pediatric development VLA2001, currently the only inactivated, adjuvanted vaccine candidate for COVID-19 in clinical trials in Europe: Initiation of pivotal Phase 3 clinical trial Participation in the world’s first COVID-19 vaccine booster trial in the UK Publication of Phase 1/2 results VLA1553, currently the only Phase 3 chikungunya vaccine program worldwide Recruitment completion for pivotal Phas...
Job Description • Initiate new EB P&S development by drafting business cases, defining P&S requirements, and documenting P&S details • Manage and define specifications and details for current and future EB P&S • Ensure that the URS of EB P&S is aligned with EB P&S Scope • Communicate and manage changes in project scope to departmental and cross functional teams • Effectively communicate and manage project expectations to team members and stakeholders • Ensure that all projects will be delivered based on the project plan and provide the related reports • Coordinate all support...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Valneva Reports FY 2020 Results and Major Corporate Achievements VALNEVAFebruary 25, 2021 GMT Excellent progress on clinical programs Unprecedented partnering deal signed with Pfizer for Lyme disease vaccine candidate VLA15, including $130 million upfront payment as part of over $300 million for upfront and milestone payments Positive initial Phase 2 results Acceleration of pediatric development announced Acceleration of chikungunya vaccine candidate VLA1553 into Phase 3 Only Phase 3 chikungunya ...